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Abstract. Influenza vaccination represents the cornerstone of influenza prevention. However, today all
influenza vaccines are formulated as liquids that are unstable at ambient temperatures and have to be stored
and distributed under refrigeration. In order to stabilize influenza vaccines, they can be brought into the dry
state using suitable excipients, stabilizers and drying processes. The resulting stable influenza vaccine powder
is independent of cold-chain facilities. This can be attractive for the integration of the vaccine logistics with
general drug distribution in Western as well as developing countries. In addition, a stockpile of stable vaccine
formulations of potential vaccines against pandemic viruses can provide an immediate availability and simple
distribution of vaccine in a pandemic outbreak. Finally, in the development of new needle-free dosage forms,
dry and stable influenza vaccine powder formulations can facilitate new or improved targeting strategies for
the vaccine compound. This review represents the current status of dry stable inactivated influenza vaccine
development. Attention is given to the different influenza vaccine types (i.e. whole inactivated virus, split,
subunit or virosomal vaccine), the rationale and need for stabilized influenza vaccines, drying methods by
which influenza vaccines can be stabilized (i.e. lyophilization, spray drying, spray-freeze drying, vacuum
drying or supercritical fluid drying), the current status of dry influenza vaccine development and the
challenges for ultimate market introduction of a stable and effective dry-powder influenza vaccine.
KEY WORDS: analytical challenges; influenza vaccine; lyophilization; needle-free dosage forms; spray
drying; spray-freeze drying; stability; stock piling for pandemics; virosomes.
INTRODUCTION
Yearly recurrent influenza epidemics and the threat of an
influenza pandemic remain major public health concerns. Few
infectious diseases cause such a huge annual toll of morbidity,
mortality, and economic loss as influenza. Each year, influen-
za affects millions of people (estimates go up to 5–15% of the
world population (1)). The symptoms of human infection
range from typical influenza-like effects, such as fever, cough,
sore throat and muscle aches, to viral pneumonia, acute
respiratory distress, and other severe and potentially life-
threatening complications (2,3). For epidemic influenza
strains this is especially true for the elderly and other high-
risk populations whereas pandemic strains may affect all age
groups.
Although antiviral drugs can be used for prophylaxis and
therapy of influenza virus infections, vaccination is recognized
as the most cost-effective method for controlling the disease.
Vaccination represents the cornerstone for influenza preven-
tion. Many countries recommend influenza vaccination
against epidemic influenza for persons who are at increased
risk for influenza complications, persons older than 65 years,
residents of nursing homes and health-care workers (4).
However, in a pandemic situation influenza vaccines are
expected to form the main prophylactic measure for all age
groups against pandemic influenza (5).
Until today, the induction of an adequate level of virus-
neutralizing antibodies in the serum is considered as the
primary criterion for influenza vaccine efficacy. These anti-
bodies are mainly directed against the major viral envelope
glycoprotein, haemagglutinin (HA). Current influenza vac-
cines are mostly inactivated formulations composed of whole
inactivated virus, split virus or subunit antigen, i.e. purified
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ABBREVIATIONS: APC, antigen presenting cell; CA, cold-
adapted; CTL, cytotoxic T lymphocyte; DC, dendritic cell; HA,
haemagglutinin; HES, hydroxyethylstarch; i.m., intramuscular; LAIV,
live attenuated influenza vaccine; M1, matrix protein of influenza;
M2, proton channel of influenza A; MDCK, Madin–Darby canine
kidney; MHC, major histocompatibility; NA, neuraminidase; NB,
protonchannel of influenza B; PBS, phosphate buffered saline;
Pc, critical pressure; POPC, 1-Palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine; RH, relative humidity; SDLM, spray dried lipid
based micro particles; SC-CO2,s u p e r c r i t i c a lC O 2;S C F ,s u p e r c r i t i c a l
fluid; SFD, spray-freeze drying; Tc, critical temperature; Tg,g l a s s
transition temperature; T
0
g, glass transition temperature of the
maximal freeze-concentrated fraction; Tm, melting temperature;
Te, eutectic temperature; VVM, vaccine vial monitor; WHO,
World Health Organization; WIV, whole inactivated virus.HA and neuraminidase (NA). However, recently also viro-
somes and a cold-adapted live influenza vaccine have entered
the market.
Today’s influenza vaccines are all formulated as liquids.
In the aqueous environment they are subjected to physical
and chemical degradation that may lead to inactivation.
Examples of such degradation processes are aggregation,
denaturation, loss of the spring-loaded conformation of HA,
hydrolysis and oxidation.
Elevated temperatures increase the rate of inactivation
of the vaccine compounds, while temperatures below the
freezing point of the dispersion cause formation of ice and
concentration of solute, processes that both may damage the
antigen. Therefore (inactivated) influenza vaccines have to be
stored within the narrow temperature range of 2 to 8°C.
This relatively narrow temperature range requires a well-
controlled cold chain, which makes the process of distribution
and storage complicated and expensive. An influenza vaccine
that is stable at ambient temperatures and not sensitive to
freezing stresses would reduce the dependency on cold-chain
facilities and would therefore be attractive for the integration
of the vaccine logistics with general drug distribution,
especially in developing countries. Moreover this would
reduce the risk of vaccine losses caused by “off-label”
storage. Overall this would result in enormous annual savings.
In addition, a stable vaccine formulation would facilitate
stockpiling of potential vaccines against pandemic viruses and
thus provide an immediate availability and simple distribution
of vaccine in a pandemic situation in both Western and
developing countries.
Current inactivated influenza vaccines are generally
administered via intramuscular (i.m.) injection, while needle-
free delivery may provide several potential advantages such
as elimination of pain and fear caused by the injection, easier
and faster vaccine distribution and administration, reduced
costs and improved immune responses including mucosal
immune responses in the respiratory tract (6–8). So far,
approaches for alternative vaccine delivery suffer from
several limitations or by practical problems that frequently
result in inadequate antibody responses or even in a state of
immunological tolerance (9). As a result, marketed influenza
vaccines, being in the liquid state, are still mainly adminis-
tered through injection. The development of new administra-
tion and targeting strategies may be facilitated by dried
vaccine formulations.
An influenza vaccine powder may have the potential to
reduce the dependency on cold-chain facilities and enable
stockpiling and vaccine targeting strategies. In general,
conversion of biologically active macromolecules, such as
proteins, vaccines and gene delivery systems into a dry-
powder formulation using suitable excipients and processes
results in more stable products which can be stored at room
temperature for longer time. In the development of new
needle-free dosage forms, such dry formulations offer the
opportunity of a more stable product, combined with the
facilitation of new or improved targeting strategies.
This paper intends to provide an up-to-date perspective
on the development of dried influenza vaccines, covering its
challenges and possibilities, including recent developments
and achievements in this field. After a brief introduction on
the structure of the influenza virus, five interrelated topics are
discussed sequentially: (1) types of influenza vaccines, (2)
rationales for the development of dry vaccine formulations,
(3) drying methods for different influenza vaccines, (4)
analytical challenges and (5) the application of dry influenza
vaccine formulations for the future.
INFLUENZA VIRUS
Structure
Influenza virus (Fig. 1) is a respiratory pathogen
belonging to the family of the Orthomyxoviridae (10). There
are three types of influenza (A, B, C) distinguished by the
antigenic differences in the major internal proteins of the
virus, i.e. nucleoprotein (NP) and matrix protein (M1). These
three types of viruses differ in their pathogenicity and
genome organization. Influenza A and B viruses are the
types that most commonly cause human disease. Among
influenza A viruses are subdivided further into subtypes
based on the surface antigens, HA and NA. In influenza A
viruses 16 subtypes of HA (H1–H16) and 9 subtypes of NA
(N1–N9) have been found to date.
The genome of influenza A and B consists of negative-
stranded segmented RNA (eight segments). Each RNA
segment is complexed with multiple copies of NP and form,
together with the polymerase complex consisting of PA, PB1
and PB2, the ribonucleoprotein (RNP) complex. In the virion
particle, eight RNP complexes are surrounded by a shell of
matrix protein (M1), which is enveloped by a lipid bilayer.
Besides the two surface glycoproteins, HA and neuraminin-
dase (NA), the envelope contains a proton channel (M2 in
influenza A and NB in influenza B). HA and NA are the
major antigenic determinants of influenza A viruses and as
such serve as the basis for subtype classification.
HA, the major surface glycoprotein of the influenza
virus, is responsible for both attachment of the virus to sialic-
acid-containing receptors on the host cell surface and fusion
of the viral and endosomal membrane. HA is a trimer
(∼225 kD) of three identical monomers (∼75 kD; Fig. 2).
Each HA monomer consists of the polypeptides HA1
(∼50 kD) and HA2 (∼25 kD), which are linked by two
Fig. 1. A schematic drawing of the influenza virus.
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central !-helical coiled-coil that forms the stem-like domain,
and three globular heads containing sialic acid-binding sites.
Each globular domain consists exclusively of HA1 folded in
highly variable loops and eight antiparallel β-strands. The
globular heads contain both the receptor binding sites and the
antigenic epitopes (11,12). NA is a tetrameric glycoprotein
(∼240 kD) consisting of a hydrophobic stalk and a globular
head that contains the enzymatic and antigenic sites (11,12).
NA cleaves sialic acid and plays an important role in
transport of the virus particles through the mucin layer lining
the respiratory tract and also mediates the release of newly
assembled virus particles (11,12).
Antigenic Drift and Shift
Antigenically altered influenza strains are constantly
formed by amino acid changes in the surface proteins, in
particular HA. RNA replication lacks proof-reading mecha-
nisms and influenza virus are therefore unable to repair
polymerase errors that occur during RNA-replication. Within
the viral genome mutations accumulate, resulting in replace-
ment of the existing by a new antigenic variant. Mutations are
seen in each of the gene products of the virus, but are most
pronounced in the surface protein HA. As a result of these
changes new influenza strains are constantly formed, that
result in yearly arising epidemics. The mechanism of acquir-
ing new influenza strains by mutations in HA is known as
antigenic drift.
In contrast to the antigenic drift, that occurs constantly,
antigenic shift occurs at irregular intervals and is defined as
the introduction of a new influenza A subtype into the human
population. Antigenic shift may be the result of either direct
transfer of a new avian influenza virus to humans or
reassortment between a human and avian virus, possibly in
an intermediate host such as the pig (13). Aquatic birds are
the natural reservoir of all known subtypes of the influenza A
virus. These birds are highly mobile and are known to carry
viruses over great distances. In addition, they transfer viruses
to other birds via the excretion of large quantities of virus in
their faeces. While often remaining healthy these birds form a
mobile pool from which intermediate hosts can be infected
with avian influenza virus. In these intermediate hosts
reassortment between human and avian viruses may occur,
resulting in new influenza strains that can infect and/or spread
from person to person (3,14). Recently, highly pathogenic
avian influenza (HPAI) viruses have been shown to infect
humans directly (zoonotic infection) without reassortment in
an intermediate host.
Antigenic shift results in influenza pandemics which
occur once in several decades. There have been three such
pandemics in the twentieth century: in 1918, 1957, and 1968.
At this moment a new highly pathogenic influenza subtype
(H5N1) is circulating in birds. This virus has so far infected
340 humans of whom 209 died (WHO, 18 Dec. 2007). These
cases are mainly found in South-East Asia. This new HPAI
subtype, which is able to infect humans but can not (yet)
spread between humans, forms a significant risk-factor for a
new pandemic (14). It is possible that an avian influenza virus
changes, so that it is able to infect humans and to easily
spread from person to person. Because such a virus has not
circulated among humans before, there is no immune
protection in the human population (15). Consequently, an
influenza pandemic may arise (16,17).
INFLUENZA VACCINES
The currently used vaccines are mainly inactivated
formulations containing at least the two viral surface antigens,
HA and NA. There are four different types of inactivated
influenza vaccines: whole inactivated influenza vaccines, split,
subunit and virosomal influenza vaccines (Fig. 3). Also a live
attenuated influenza vaccine is on the market (18–20). The
seasonal vaccines are trivalent, containing the antigens from
two subtypes of influenza A and one subtype of influenza B
as recommended by the World Health Organization (WHO).
To ensure an antigenic match with new circulating influenza
viruses, the composition of these trivalent vaccines is updated,
on the basis of WHO’s worldwide surveillance of new
influenza strains twice a year. Following vaccination with
influenza A, around 90% of normal subjects achieve serum
haemagglutination inhibition (HI) titers higher than 40, a
level generally associated with a 50% reduced chance of
contracting influenza. Implemented criteria for vaccine im-
munogenicity are based on the induction of an adequate level
of virus-neutralizing antibodies (21).
The influenza virus for vaccine production is generally
produced by propagation of virus in embryonated hen’s eggs,
although recent developments include vaccine virus produc-
tion in cultured cells, such as Madin–Darby canine kidney
Fig. 2. The three-dimensional structure of the influenza HA. The HA
monomer (left) and trimer (right). This figure was produced by André
van Eerde (University of Groningen), using MOLSCRIPT, on basis
of the co-ordinate file from the Protein Data Bank, code 3HMG.
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fibroblasts) or Per.C6 cells (human fetal retinoblast immor-
talized by transfection with an E1 minigene of adenovirus
type 5) (22–25). The virus (in allantoic fluid or medium) is
harvested, concentrated and purified. The virus is subse-
quently inactivated with formaldehyde or β-propiolactone
and processed to the vaccine type of choice.
Whole Inactivated Virus Vaccine
Whole inactivated virus (WIV; Fig. 3) vaccines contain
inactivated influenza virus particles (virions) retaining the
receptor binding and membrane fusion activity of the native
virus. These vaccines contain all the components of the active
virus and have the same physical structure as the active virus.
However, no replication occurs, since replication is blocked
due to modified nucleic bases (mainly purines) in the viral
genome caused by the virus-inactivation step with formalde-
hyde or β-propiolactone (26).
Vaccination with WIV activates both the humoral and
cellular arm of the adaptive immune response and WIV has
been shown to be more immunogenic than split or subunit
vaccines (4,27–31). The activation of the cellular arm of the
adaptive immune system is probably caused by virtue of their
particle-like structure and membrane fusion activity (21).
Although cell-mediated immunity does not seem to contrib-
ute significantly in preventing infection, it plays a role in the
recovery from influenza infection and may prevent influenza-
associated complications (4). Besides the fact that WIV
vaccines are highly immunogenic, they are expected to induce
more subtype cross-reactive cellular responses directed against
conserved epitopes in internal influenza proteins (4,32–34). A
disadvantage of WIV vaccines, in comparison with split or
subunit formulations, is that they are associated with more
frequent adverse effects, like pain and redness at the injection
site or fever. Therefore, WIV vaccines are less suitable for the
use among young children. The current use of WIV vaccines
is limited and in many countries they are not licensed (35).
However, WIV is regarded as a promising candidate pan-
demic vaccine (36).
Split/Subunit Vaccine
Today, most inactivated influenza vaccines are supplied
as split vaccines, produced from chemically disrupted influ-
enza virus, or as subunit vaccines containing predominantly
purified HA and NA (Fig. 3). Millions of doses of these
influenza vaccines are administered by intramuscular or
subcutaneous injection throughout the world each year.
These vaccines trigger the humoral immune system result-
ing in the production of serum antibodies directed against
HA and NA. These serum antibodies play a role in both
resistance to and recovery from influenza infection (4). The
overall rate of adverse reactions to split or subunit vaccine is
low. As a result the use of split or subunit preparations is
first choice in children younger than 9 years. However, as
pandemic vaccine for the H5N1 subtype, non-adjuvanted
split and subunit formulations appear to be poorly immuno-
genic (36).
Virosomal Vaccines
A relatively novel class of inactivated influenza vaccines
is the virosomal influenza vaccine. Virosomes are virus-like
particles, consisting of reconstituted influenza virus enve-
lopes, which do not contain the genetic material of the native
virus (Fig. 3)( 21). Virosomes are produced from solubilized
and subsequently reconstituted membranes of influenza virus
(37–39). If produced properly, reconstituted virosomes retain
the HA-mediated cell binding and membrane fusion proper-
ties of the native virus. As a result virosomes, like WIV,
possess the functional characteristics, such as the particle-like
structure, repetitive arrangement of the antigens on the
virosomal surface and the fusion activity, which may induce
enhanced immunogenicity (21). As a result, virosomes induce
both virus-neutralizing antibody titers and prime the cellular
arm of the immune system.
Recently commercial virosomal influenza vaccines have
become available under the trade names Inflexal V
® and
Invivac
®. Compared to conventional inactivated subunit
influenza vaccine, local reactions at the site of injection (e.g.
pain, swelling) are reported at a lower frequency with
virosomal vaccines, whereas the reporting rates of systemic
side effects (e.g. fever, headache) are comparable between
the two vaccine types (40,41).
Live Attenuated Influenza Vaccines
Besides the inactivated vaccines, also a live attenuated
influenza vaccine (LAIV; Fig. 3), such as the recently in the
USA authorized Flumist
®, are on the market (19,20)I n
contrast to the inactivated influenza vaccines which are
administered by intramuscular or subcutaneous injection,
LAIV is administered intranasally (0.25 ml in each nostril).
Administration of LAIV is preformed via a spray device that
produces aerosols with large droplets which are deposited in
the nasopharynx (19). Flumist
® contains the genes encoding
the six internal segments from an attenuated donor strain
Fig. 3. Schematic drawings of WIV, split, subunit and virosomal vaccine.
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proteingenes (HA and NA) from the wild-type virus. The
donor strain is cold-adapted (ca) and as such capable to grow
in human nasal cavities (±32°C) but not in internal organs
such as the lungs (>37°C) (19). The underlying idea of
vaccination with LAIV via the upper respiratory tract (nose)
is to induce a secretory and systemic immune response that
more closely resembles the immune response observed after
natural infection. LAIVs induce a broad mucosal and
systemic immune response. This in contrast to the current
inactivated influenza vaccines, which only stimulate the
systemic but not the mucosal immune system (4). On the
other hand, LAIV nasal vaccines and inactivated i.m.
vaccines are found to have similar efficacy in preventing
influenza illness from homologous virus infections (42,43).
Compared to injected inactivated influenza vaccines, LAIVs
are believed to provide broader immunity against circulating
heterologous virus strains. The feature of LAIV virus to
replicate and the possibility to prime the immune system of
naive persons, may result in a vaccine that is more immuno-
genic in young children than inactivated vaccines (4). To date,
it is unclear whether LAIV vaccines are also safe in immuno-
compromised patients (4).
RATIONALE FOR THE DEVELOPMENT
OF STABILIZED VACCINE FORMULATIONS
In the liquid state, the stability of influenza vaccine is
limited. In general, the stability of new vaccine compositions
is tested by the manufacturer in order to support regulatory
filing and for GMP compliance. The stability is determined by
investigation of the content of HA antigen, presence of NA,
pH, content of preservative (if applicable) and appearance.
The shelf-life of the product is based on the most sensitive
parameter, in general the HA content (HA potency)(44).
Stability studies are generally performed according to ICH
guidelines (45,46). Stability depends among others on vaccine
strain (47), pH, addition of stabilizers such as gelatin or
polysorbate, compatibility of the product with container and
closure and treatments needed to reduce adsorption or
interaction with the container (44). Most inactivated influenza
vaccinesarestableforabout1yearintherefrigerator(2to8°C).
In contrast to inactivated influenza vaccines, LAIV must be
stored frozen (−15°C to −25°C). To overcome the freezing
stresses, the vaccine is stabilized with phosphate glutamate
buffer, containing sucrose. Before use the vaccine must be
thawed (for up to 60 h at 2 to 8°C) and should not be refrozen.
However, a refrigerator stable formulation is in development
(44,48).
Cold Chain
Inactivated influenza vaccines are temperature-sensitive
and must be stored at 2 to 8°C. Elevated temperatures can
cause inactivation of the vaccine antigens, while temperatures
below freezing result in formation of ice and concentration
of solutes that may cause denaturation of the antigen (47,49,
50). Because high as well as low temperatures can be
detrimental, influenza vaccines have to be stored within a
narrow temperature range. This narrow temperature range
makes the process of distribution and storage complicated,
vulnerable and costly. Although it has been demonstrated
that the influenza subunit vaccine can be stored for a couple
of days outside the refrigerator at room temperature (47),
vaccine distribution remains one of the greatest risk for
vaccine quality, especially when the vaccine leaves the central
storage depots. During transport and storage at the local level
the risk of storage outside the temperature range (2–8°C)
increases. Freeze-sensitive vaccines are still shipped with
frozen ice packs and/or improperly conditioned ice packs
pose the risk that the vaccine will be exposed to freezing
temperatures. Improper storage is not easily detected. In
certain cases damage (especially aggregation) induced by
heat or freezing can be detected visually (Fig. 4), with or
without a shake-test. However, in many cases no clear visual
changes are observed (51). Time-temperature indicators,
vaccine vial monitors (VVMs) can prevent usage of vaccines
that were stored too long at elevated temperatures. An
influenza vaccine formulation that would be stable at room
temperature, or even somewhat higher temperatures (up to
35°C), and be insensitive to freezing stresses, would reduce
the dependency on cold-chain facilities. Such a vaccine would
considerably simplify vaccine distribution and enable the
integration of vaccine logistics with general drug distribution,
especially in developing countries. Moreover, this would
reduce vaccine losses. Both aspects would result in enormous
annual cost savings.
Stock Piling
Recent outbreaks of HPAI virus infections in poultry
have raised concerns that a new influenza pandemic might
occur in the near future. The key preventive method to
protect the population against a pandemic virus is an
influenza vaccine (52). In the most extreme scenario,
adequate pandemic preparedness would demand the avail-
Fig. 4. Visual observation of freeze-induced damage caused by
accidental storage below 0°C. The left bottle contains the original
subunit vaccine. The right bottle contains the freeze-damaged subunit
vaccine. The freeze-thaw cycle resulted in a turbid, less opalescent
vaccine solution.
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people) to vaccinate the entire world population. However,
today’s global production capacity for a trivalent influenza
vaccine is around 300 million doses per year and the time
needed until the first vaccine dose can be used is at least
4 months (10,53). As a result the WHO has encouraged
individual countries to produce a pandemic preparedness
plan. Such a plan would guarantee fair distribution of vaccine
and pre-organized vaccine supply in a clearly defined manner.
A new feature discussed in the context of pandemic
preparedness is stockpiling of vaccine from different influenza
A virus strains (e.g. H5, H7 and H9) assuring immediate
availability (52,53). Although such vaccines may not be a
perfect match to a newly emerging influenza A virus variant,
a certain degree of intra-subtypic immunity and immunolog-
ical priming is expected to ameliorate the effects of an initial
pandemic wave. Current seasonal (inactivated) influenza
vaccines have a shelf-life claim of 1 year only. In contrast,
stable vaccine formulations of the H1–H16 subtypes would
not only reduce the dependency on the cold chain, but could
also increase the shelf-life of stockpiled vaccines considerably.
As a result such a stable vaccine formulation would facilitate
stockpiling of potential vaccines against epidemic and pan-
demic viruses. Consequently, this would provide in immedi-
ately available and readily distributable vaccine in a pandemic
situation.
Non-parenteral Dosage Forms
For mass vaccination against influenza, especially in case
of a pandemic, the use of a non-parenteral influenza vaccine
might be preferable for several reasons. Non-parenteral
administration, simplifies the logistics of immunization and
improves the immunization coverage as has been shown by
the success of the oral polio vaccine (54). The ease of use and
cheap administration of the oral (live) polio vaccine in
vaccination programs, contributed to the successful world-
wide polio reduction. Non-parenteral dosage forms would
make administration of influenza vaccines safer during
vaccination programs, since iatrogenic infections due to
needle-stick injuries or the use of unsterile needles, which
are especially a high risk in third-world countries, cannot
occur (6,55).
In addition, it has been shown that administration of
influenza vaccines via non-parenteral routes like the nasal,
oral or pulmonary route has the potential to induce and to
promote mucosal and systemic humoral as well as cell-
mediated immune responses. In contrast to parenteral
vaccination, mucosal vaccination has the potential to induce
secretory IgA antibody responses in the respiratory tract and
the oropharyngeal region. Since mucosal IgA responses have
been shown to exhibit cross-protective immunity against
antigenically distinct viruses (56,57), these vaccinations might
give protection not only against homologous virus, but also
against drifted, heterologous strains.
In the development of new needle-free dosage forms,
dried influenza vaccine formulations offer not only the
opportunity of a more stable product, but also facilitate new
or improved targeting strategies of the vaccine compound.
State of the art technologies, like formulation technologies
(tablets with dried vaccine incorporated and supplied with
special coatings; powders designed for nasal or pulmonary
delivery) and the use of special designed delivery devices
might enable efficient targeting of the vaccine to specific sites
in the human body. Consequently, the immediate or sustained
release and/or increased residence time of the vaccine
compound at the desired place might result in improved
immune responses.
METHODOLOGIES FOR STABILIZATION
OF INFLUENZA VACCINES
The most commonly used method to stabilize biologically
active macromolecules, such as proteins, vaccines and gene
delivery systems, is to convert them to dry powders. In general
biopharmaceuticals are more stable in the solid state than in
the liquid state. This is believed to be related to the reduced
mobility of the biopharmaceutical and the absence or reduc-
tion of certain degradation pathways such as hydrolysis.
However, depending on the drying method, freezing and/or
drying stresses may affect the structural integrity and thereby
activity of the biopharmaceutical. Accordingly, appropriate
stabilizers are required for preservation of these properties. It
is well known that sugars can stabilize proteins (58–63), lipo-
somes, lipoplexes (64–69) and various viruses (70–73) during
drying and subsequent storage. If dried properly, the active
substance, complex or vesicle is incorporated in a matrix
consisting of amorphous sugar in its glass state. The sta-
bilizing effect of these sugar glasses has been explained by the
formation of a sugar matrix which acts as a physical barrier
between particles (particle isolation) and strongly reduces
diffusion and molecular mobility (vitrification). Both the physical
barrier (74) and the lack of mobility provided by the glass
matrix (75), prevent aggregation and degradation of the
biopharmaceutical. Moreover, during the drying process, the
sugar replaces the water molecules in the hydrogen-bonding
interaction with the active material, such that the structural
integrity of the drug is preserved (76). Under dry conditions,
the glass matrix is maintained as long as the temperature is kept
well below the glass transition temperature (Tg), which is
characteristic for the stabilizing sugar used.
Potentially there are several different drying methods
that can be used to convert the liquid influenza vaccine (with
the required excipients) into a stable powder. Each of the
methods has typical advantages as well as drawbacks, of
which the relevance and magnitude are further determined by
the applied process conditions as well as the formulation
(excipients used). A number of aspects determine the
suitability of a specific drying method. Most important in this
respect are process stresses, crystallization risk, process
speed, ease to design particles, capacity, recovery, costs and
current (industrial) experience.
In the past decades several papers have been published
in which dried influenza vaccines were used. Most of these
dried influenza vaccines were produced in order to facilitate
new needle-free dosage forms for nasal, pulmonary or epi-
dermal delivery. The integrity and stability of the influenza
vaccine compound after drying has been examined in only a
limited number of the published articles. From these studies it
is difficult to draw definitive conclusions with regard to the
influences of process and formulation parameters on vaccine
integrity and stability. However, it is possible to extrapolate
1261 Development of Stable Influenza Vaccine Powder Formulationsnotions described in the literature concerning drying of
biopharmaceuticals. In the proceeding paragraphs an over-
view of the suitability of the major drying methods for
influenza vaccines will be given based on general concepts
concerning drying of biopharmaceuticals (as summarized in
Table I) and the few dried influenza vaccines described in
literature (as summarized in Table II).
Freeze Drying and Spray-Freeze Drying
The Process
Generally, freeze-drying (lyophilization) is the preferred
drying method for biopharmaceuticals (89). Freeze-drying is a
process by which the material is frozen and subsequently
dried by the removal of water by sublimation (directly from
the solid phase to gas) under reduced pressure. As stated
above, for successful drying of biopharmaceuticals a stabiliz-
er, such as a sugar is needed to protect the biopharmaceutical
both during drying and subsequent storage.
The principle of sugar glass production by lyophilization
is illustrated by the state-diagram of a binary sugar/water
system presented in Fig. 5. The figure is illustrative for the
process by which a biopharmaceutical is incorporated in a
glassy matrix of sugar using lyophilization. However, for the
sake of clarity the contributions of the biopharmaceutical and
compounds such as buffers and salts are neglected in the state
diagram.
Upon cooling of a sugar solution of composition A,
water starts to crystallize below 0°C (point B) due to freeze
point depression caused by the solute. During freezing, the
crystallization temperature gradually decreases because
the remaining solution becomes more concentrated. At the
eutectic temperature (Te, point C) the sugar should start to
crystallize simultaneously with the water molecules if the
solution would be in thermodynamic equilibrium. However,
when the solution is rapidly frozen, e.g. in liquid nitrogen or
dry ice, the crystallization rate is too low for the sugar to form
crystals. As a consequence, rapid cooling below the Te results
in further crystallization of water only and so-called freeze
concentration of the sugar continues. At the glass-transition
temperature of the maximally freeze-concentrated fraction
(T
0
g , point D), the viscosity increases dramatically resulting in
immobilization of the sugar and water (and further compo-
nents), and a glass is formed. In this glass the sugar molecules
are randomly orientated (amorphous state) and form a
vitrified matrix in which water and biopharmaceutical are
captured. Due to the high viscosity of the amorphous matrix
also water molecules are not able to crystallize anymore.
Consequently, the composition of the glass remains the same
upon further cooling (D→E).
To obtain the biopharmaceutical in a dry amorphous
glass, the frozen sample is kept under vacuum and water is
removed by sublimation. During primary drying, the first
stage of the freeze drying process, the ice formed during
freezing of the sample is removed. The temperature during
this primary drying must be kept below the T
0
g . This is
essential because above this temperature the sugar glass turns
into the rubbery state in which the molecular mobility is
considerably increased and crystallization of the sugar or
phase separation may occur. This is detrimental for the
stabilization of the incorporated biopharmaceutical com-
pound since hydrogen bonds or other stabilizing interactions
with the sugar are lost and the translational freedom of the
biopharmaceutical increases, which could cause aggregation.
In addition, the mechanical forces induced by crystallization
of the sugar may damage the structure of the biopharma-
ceutical compound, which in turn may lose functional activity.
The remaining water molecules captured in the glassy
matrix upon rapid cooling are removed during the secondary
drying when the glass surface is free of ice. During this
secondary drying the temperature can be slowly increased as
long as the temperature is below the Tg of the water-
containing product (E→F). After removal of all water, the
biopharmaceutical compound is incorporated in a dry sugar
glass with a Tg depending on the sugar used. To assure a long
shelf-life, the dry formulation should be stored well below its
Tg to avoid transition into the rubbery state (which could
result in crystallization). Moreover, generally a highly porous
cake with a high specific surface area is obtained after
lyophilization, which can be easily reconstituted. However,
this porous cake also easily absorbs water. As a result the
product should be kept at a low relative humidity (adequate
packaging required), since absorbed water decreases the Tg
of the formulation (see glass transition curve as function of
water content).
Spray-freeze drying (SFD) is a relative new drying
process to produce biopharmaceutical powders that combines
atomization, generating a cloud of small droplets (leading to
rapid freezing), and lyophilization. The state-diagram of
incorporation of a biopharmaceutical in a glassy matrix of
sugar by SFD is the same as that of conventional lyophiliza-
tion (Fig. 5). A liquid solution containing a biopharmaceutical
compound and stabilizer(s) is atomized into a cryogenic
medium, in general liquid nitrogen, to vitrify the droplets
(A→E), followed by removal of ice and water molecules
captured in the glassy matrix by lyophilization (E→F). A
main advantage of SFD over normal freeze drying is the
Table I. General Concepts Concerning Drying of Biopharmaceuticals
Atomization
Stress
Freezing
Stress
Heating
Stress
Process
Speed
Crystallization
Risk
Particle
Design Capacity Costs
Industrial
Experience
Freeze drying + − + − + − ± − +
Spray-freeze drying − ++ ± + +± −−
Spray drying − + − + − ++ ++
Vacuum drying + + ± −−− ±+ +
Supercritical fluid drying − +± + ± ++ −−
+, Favorable; −, Unfavorable
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1263 Development of Stable Influenza Vaccine Powder Formulationsextremely rapid vitrification (fast A→E traject) due to the
enormous surface area for heat (energy) transfer generated
during the atomization (the spraying process) and a direct
contact of the liquid droplets with the freezing medium. This
is important since rapid vitrification prevents phase separa-
tion. Moreover, the large surface area allows rapid drying.
Another advantage of SFD is the capability to produce
particles with adjustable sizes which can be used for certain
drug delivery strategies such as epidermal powder delivery
and dry powder inhalation.
Lyophilization and SFD are not processes without
concerns. Typically, freezing and drying pose stress on the
compounds involved. In response to freezing, multiple ice
crystals of various sizes grow and interact with the freeze-
concentrated fraction (the highly viscous fluid phase contain-
ing non-crystalline components and the remaining non-frozen
water).Duringthisprocess, a large ice/liquid interface iscreated
that presents a surface area for protein adsorption. This may
result in conformational changes and disruption of the vaccine
compound. Moreover, the solute concentration of the non-
frozen fraction increases during freezing, resulting in accelera-
tion of reaction kinetics (90) and changed physical properties
such as ionic strength and relative composition of the solution,
which may further destabilize the vaccine (89,91).
In the development of lyophilized biopharmaceuticals,
the choice of buffer type can be of major importance (50,89,
92). Phosphate-buffered saline (PBS) is an often used buffer.
However, due to crystallization of sodium or potassium
dibasic phosphate, the pH of the PBS formulation shows a
downshift during freezing. When the biopharmaceutical is
sensitive for pH changes this shift may lead to destabilization
or inactivation of the compound (50,89,92). Buffer systems
composed of organic molecules generally do not induce pH
change during freezing. However, the T
0
g and the Tg can be
strongly lowered by them (92).
In the case of SFD, air–water interfacial stresses and
shear stresses induced by the atomization of the feed solution
may lead to destabilization of the compound. Biopharma-
ceuticals, vaccine compounds such as HA, NA and lipids,
being amphiphilic membrane components are surface-active.
As a result, the compounds tend to adsorb at the air–water
interface (the fine droplets have a high specific surface area)
where the large surface free energy may cause the biophar-
maceutical to be disrupted and to expose its hydrophobic
regions resulting in aggregation (93).
Besides the risk of losing the structural integrity of the
biopharmaceutical during the drying process, other disadvan-
tages of lyophilization are the long process time and the high
energy costs.
Freeze Drying and Spray-Freeze Drying of Influenza Vaccine
Freeze drying and spray-freeze drying have been used for
drying of various influenza vaccine formulations (Table II).
Subunit and split vaccines have been successfully (spray-)
freeze dried with conservation of the antigen’s molecular
structure, potency and/or antigenicity in mice (50,77–79).
However, during lyophilization various process factors
can affect the integrity of the vaccine compound. HA in
influenza subunit vaccine is susceptible to freezing stresses,
when no stabilizers are used, especially at low freezing rates
(49,50). However, it has been shown that sugars (trehalose,
inulin and dextran) can prevent freeze-induced damage (50).
They revealed with tryptophan fluorescence spectroscopy,
circular dichroism spectroscopy and a proteolytic assay,
that changes in secondary and tertiary structure of HA
caused by freezing were absent when sugars were added
before freezing.
In the development of lyophilized influenza vaccines the
choice of buffer type has been shown to be of major
importance (50). By nature, HA within the influenza virus
possesses a spring-loaded conformation that changes upon
acidification in the endosome (pH∼5) in order to mediate
fusion of the virus with the endosomal membrane. As a result
HA is sensitive to the pH drop during freezing, when PBS is
used as buffer. The irreversible conformational changes of
HA during freezing can be prevented by the use of another
buffer, Hepes buffered saline (HBS), which does not show
strong pH changes during freezing (50). Moreover, a fast
freezing rate and the use of sugars, like trehalose, inulin or
dextran, are aspects that may contribute to the successful
production of vaccine powder with conservation of the
structure of HA (50).
Maa et al. produced a vaccine powder of a trivalent split
vaccine by SFD using combinations of carbohydrates. They
found that combinations of trehalose, mannitol and dextran
at different concentrations (20–30% w/v) were capable to
preserve during SFD the antigen’s potency as well as
immunogenicity in vivo (79).
WIV vaccine has been successfully lyophilized by Huang
et al.. They lyophilized a mixture of WIV and trehalose in a
ratio of 1:500 (10 μg virus/5 mg trehalose) from sterile saline.
After lyophilization, subsequent milling and reconstitution
the whole virions retained their haemagglutination capacity
with chicken erythrocytes (85).
Influenza virosomes were lyophilized by De Jonge et al.
(88,94). Virosomes (225–450 μg/ml) prepared from A/
Panama virus were lyophilized with inulin 1.8 kD (22.5–
45 mg/ml) in a ratio of 1:100 (w/w). These lyophilized
virosomes retained their fusogenic properties in vitro and
Fig. 5. Lyophilization—state-diagram of a binary sugar/water system
and the incorporation of a biopharmaceutical in a glassy matrix of
sugar [freezing (A→E) and drying (E→F)]: A, starting composition;
B, point where freezing of water starts; C, eutectic point (Te); D,
maximally freeze concentrated fraction at its glass temperature T
0
g

;
E, maximally freeze concentrated fraction below its glass temperature
T
0
g

; F, lyophilized formulation.
1264 Amorij et al.antigenicity in mice. In contrast, lyophilization of virosomes
without protectant resulted in reduced fusogenic properties
and disruption of the vesicular structure of the virosomes.
Spray Drying
The Process
Spray drying is the process of drying a liquid feed into
dry particles through atomization of the feed (generating a
cloud of small droplets) into a hot drying gas. Usually air is
used, but sensitive materials and solvents like ethanol may
require oxygen-free drying with nitrogen gas instead. Spray
drying can be used for biopharmaceuticals. The incorporation
of a biopharmaceutical in a glassy matrix of sugar by spray
drying is illustrated by the state-diagram of a binary sugar/
water system presented in Fig. 6. The contribution of the
biopharmaceutical is neglected, since it is usually present in
low amounts. While with lyophilization the biopharmaceutical
is rapidly vitrified by application of low temperatures, with
spray drying the biopharmaceutical is rapidly vitrified by
using a large liquid–gas interface at elevated temperature (a
rapid moisture removal).
Spray drying starts with atomization of a sugar solution
of composition A (and temperature A) in the hot air of the
spray dryer. By atomizing the solution a cloud of droplets is
created. Just after atomizing, the droplet surface is moisture-
saturated and by the endothermal process of water evapora-
tion the droplet temperature remains significantly lower than
the hot air temperature. During evaporation of the water the
remaining concentration of sugar in the droplet increases
(A→B). Simultaneously the droplet temperature begins to
rise (A→B) since water diffusion to the surface cannot keep
the surface moisture-saturated, while due to the endothermic
heat of evaporation the air temperature significantly decreases.
At a certain concentration (point B) the sugar should become
solid (e.g. by crystallization or amorphous precipitation)
simultaneously with the evaporation of the water molecules
under conditions that the solution is in thermodynamic equilib-
rium. However, when the evaporation rate of water is fast
enough, there is no sufficient time for the sugar to crystallize by
which the solution will pass through the rubbery state (B→C)
and turn into the dry amorphous glassy state.
Spray drying is not a process without concerns. Firstly,
the biopharmaceutical may suffer from heat denaturation by
hot air. Although the droplet temperature only increases
marginally as a result of energy consumption during evapo-
ration of water, it is wise to use process parameters that are
well matched in order to assure that the outlet temperature is
not too high thereby reducing the risk of denaturation/
degradation of the vaccine compound. Secondly, air–water
interfacial stresses and shear stresses induced by the atom-
ization of the feed solution, just as with SFD, may lead to
degradation of the biopharmaceutical. Therefore, the addition
of surface-active agents (surfactants) to the mixture before
spray drying has been used to remove proteins from this
interface and consequently improve their stability (90,95,96).
Again the use of carbohydrates may prevent deteriora-
tion by increasing unfolding temperatures of the (proteina-
ceous) biopharmaceutical. Various sugars or polyols can be
used for the spray drying of proteinaceous compounds.
During spray drying mono- and disaccharides or small polyols
with a low Tg have the tendency to crystallize resulting in
degradation of the biopharmaceutical (95,97–99). However,
formulations that crystallize less easily and have a high Tg can
be made (100–103).
Spray Drying of Influenza Vaccines
Spray drying has been used to prepare dried influenza
subunit and WIV vaccines. Recently, an influenza subunit
vaccine powder was prepared by spray drying using the
oligosaccharide inulin (inulin 4 kD, Tg of 156°C). A solution
of subunit vaccine (A/Panama H3N2; 275 μg/ml) and inulin
(55 mg/ml) in PBS was spray dried using a Mini Spray Dryer.
The vaccine powder obtained after spray drying consisted of
spherical and smooth particles with an average particle size of
3 μm. Moreover, the process stresses did not have an adverse
effect on the antigen’s immunogenicity in vivo (unpublished
results shown in Fig. 7).
Spray-dried lipid-based microparticles (SDLM) have
been used to encapsulate subunit and WIV vaccine in
microparticles in order to target APC in the respiratory tract
(9,87). Besides vaccine these microparticles contained lipid-
surfactants, dipalmitoylphosphatidylcholine and distearoyl-
phosphatidylcholine (75–85% w/w; both surfactants occur in
the lung), and a polysaccharide, hydroxyethylstarch. The
release of antigens (pharmaceutical availability) from these
SDLMs was limited, but co-formulation with the biocom-
patible surfactant tyloxapol improved the immune profile
of these particles (9). However, it is unclear whether the
structural integrity of the vaccine compounds was affected by
the drying process, since only a bioassay based on peptide
recognition and SDS-treatment was used to determine the
antigen content. In particular, due to their particulate nature,
WIV but also virosomes may possess a higher sensitivity to
shear stresses during atomization applied by spray (freeze)
drying than subunit and split vaccines being proteinous
vaccines. The bioassay used does not reveal whether the
WIV particles are still intact after the drying process.
Fig. 6. Spray drying—state-diagram of a binary sugar/water system
and the incorporation of a bio-pharmaceutical in a glassy matrix of
sugar (A→C, assuming a homogeneous composition within the
droplets). A, starting composition; B, point where the sugar solution
(in the droplets) passes the crystallization curve of sugar; C, spray
dried product in the amorphous glassy state.
1265 Development of Stable Influenza Vaccine Powder FormulationsVacuum Drying and Desiccation
The Process
Vacuum drying or vacuum evaporation is the process of
drying at a pressure where the boiling point of water has been
lowered to below the sample temperature. The incorporation
of a biopharmaceutical in a glassy matrix of sugar by vacuum
drying (and desiccation) is illustrated in Fig. 8.
A liquid solution of composition A is subjected to low
pressure (<3.17 kPa at 25°C) and starts to boil. Constant
addition of heat is necessary to prevent the sample to cool
from heat loss by evaporation. At a certain point the sugar
solution is saturated (point B); the sugar should start to
precipitate simultaneously with the evaporation of the water
molecules when the solution is in thermodynamic equilibri-
um. However, when the evaporation rate of water is fast
enough, there is no sufficient time for sugar crystallization, by
which the solution will pass through the rubbery state (B → C)
and turn into the dry amorphous glassy state.
Desiccation is the process of drying using a hygroscopic
substance (a desiccant) in a sealed container (desiccator).
During desiccation small amounts of material are dried on a
shelf above a drying agent or desiccant, such as dry silica gel or
anhydrous caustic soda. Just as vacuum drying this drying
processiscarriedatroomtemperatureorelevatedtemperatures.
In contrast to spray drying that proceeds very rapidly,
vacuum drying and desiccation can take hours. As a result the
risk of sugar crystallization and/or phase separation in the
rubbery state increases. Moreover, during vacuum drying
large-air–liquid interfaces are created by the boiling of the
solution, which increases the risk of adsorption of the
biopharmaceutical at this interface and subsequent denatur-
ation. Despite these increased risks, it should be realized that
these drying methods offer the opportunity to dry without
heating or freezing stresses and can be performed at low costs.
Vacuum Drying and Desiccation of Influenza Vaccines
Air drying and desiccation have been used for preparing
dry subunit and split influenza vaccines. In different labora-
tories, subunit vaccine has been air dried after dispersing
0.5 ml vaccine on 1 g D-xylose (80,84). Chen et al. prepared
dried split vaccine powder by desiccation a vaccine in
trehalose (100 mg/ml) solution overnight using an N2 purge
(82,83). Although these researchers performed immunization
studies it was not investigated whether the integrity of the
vaccine compound in their dried product was affected. The
maintenance of the integrity of the vaccine compound is a
concern with these specific drying techniques. As mentioned
above, the long drying time increases the risk of phase
separation and/or crystallization, especially when small poly-
ols like D-xylose and trehalose are used (98,104–106).
Supercritical Drying
A relative new drying method is supercritical fluid (SCF)
drying (reviewed in: (107) and (108)). Although until now no
influenza vaccines have been dried by supercritical drying,
supercritical drying is a drying method with considerable
potential that has been successful applied for several bio-
pharmaceuticals. Examples are Diphtheria toxoid and live-
Fig. 8. Vacuum drying and dessication—state-diagram of a binary
sugar/water system and the incorporation of a biopharmaceutical in a
glassy matrix of sugar at a constant (isothermal) temperature (A→C).
A, starting composition; B, point where the sugar solution passes the
crystallization curve of sugar; C, dried product in the amorphous
glassy state.
Fig. 7. Spray dried influenza subunit vaccine. The vaccine was dried
with inulin as stabilizer, using a 5.5% w/v sugar solution at a ratio
sugar/HA=200 w/w. a Vaccine antigenicity of spray dried influenza
subunit vaccine. Subunit antigen-specific IgG serum titers (black
bars) and serum HI titers (grey bars) in Balb/c mice. Animals were
immunized i.m. (on days 0, 14 and 28) with 5 μg subunit antigen (A/
Panama) from unprocessed (n=4) or reconstituted spray dried
subunit vaccine (n=8). On day 52 mice were sacrificed and titers
were determined according to (49). The results are expressed as the
geometric mean titer ± standard deviation for each group. b Scanning
Electron Micrograph of spray dried influenza vaccine particles.
Magnification of ×20.000, average particle size is ∼3 μm.
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SCF drying makes use of a fluid that is supercritical i.e.
when both pressure and temperature are above the critical
pressure (Pc) and critical temperature (Tc), respectively
(Fig. 9). Above the critical temperature, it is not possible to
convert a gas in the liquid state by increasing the pressure.
However, the density of the gas increases continuously with
increasing pressure and can be higher than that of a liquid at
ambient conditions. The supercritical fluid has gas-like
physical properties, such as a high diffusity and low viscosity
(111). The application of SCFs by pharmaceutical companies
isrestricted to supercritical CO2 (SC–CO2), because this SCF is
generally regarded as safe by the FDA, available in large
quantities at high purity, inexpensive and has a low Tc (31.5°C)
etc. There are two main principles of SCF drying which may be
applicable for drying and formulation of influenza vaccines.
The first concept is spray drying in a supercritical fluid. A
vaccine and sugar containing solution is sprayed by atomiza-
tion into a vessel containing SC–CO2. Although SC–CO2 is
not completely miscible with water it dissolves in the vaccine
sugar solution. However, the vaccine compound and sugar
are poorly soluble in SC–CO2 (antisolvent). As a result the
solvent in the vaccine sugar droplets loses solvent power and
becomes supersaturated. This in combination with the water
transfer from the supersaturated droplets to the SC–CO2
(extraction) leads to the incorporation of the vaccine com-
pound in a glassy matrix of sugar. Critical in this process is the
mass transfer of water to ensure a rapid dehydration in order
to prevent crystallization of the stabilizing sugar. The mass
transfer can be improved by decreasing the droplet size,
decreasing the relative velocity between the droplets and SC–
CO2 and increasing the SC–CO2/vaccine sugar solution ratio
(108). Another critical issue in the drying process is the pH
drop (final pH 2.5–3) due to the dissolution of CO2 in the
water phase (108). Since the structure of HA changes below a
pH of approximately 5, it is essential to use a sufficiently
buffered vaccine solution.
In the second concept, the SC–CO2 is dissolved at high
pressure in the solution containing the vaccine compound and
sugar and sprayed to atmospheric conditions. Upon spraying,
the CO2 expands and droplets break up in smaller droplets,
which are then dried by a flow of nitrogen. This process is a
spray-drying process at relative low-temperature (20–50°C, but
usually somewhat above Tc (32°C) (108)), using the SC–CO2 as
effervescent and extraction agent to enhance the atomization
process and water transfer thereby shortening the drying
process.
STORAGE STABILITY OF DRIED INFLUENZA
VACCINES
Although the drying process may not affect the structural
characteristics of the vaccine, it does not guarantee long-term
stability. In the dry state, the long-term stability of the
influenza vaccine may still be limited, especially at elevated
storage temperatures. The stability of the dried vaccine is
mainly dependent on the formulation (composition), the struc-
ture in which the vaccine is incorporated in the formulation
and, of course, the storage conditions.
It was shown that the storage stability of lyophilized
influenza subunit vaccine was dependent on the type of
carbohydrate, type of buffer and storage conditions (50).
Subunit vaccines lyophilized with trehalose, inulin 0.9 kD or
inulin 1.8 kD have been shown to be stable for at least
26 weeks at room temperature. In contrast, vaccine incorpo-
rated in a glassy matrix of dextran 56 kD lost its potency
during storage for 26 weeks. When influenza subunit vaccine
lyophilized with inulin 0.9 or 1.8 kD was stored at 45°C, the
potency of the vaccine was almost completely lost within
4 weeks. In contrast, when trehalose was used as stabilizer the
subunit vaccine retained its potency at this temperature for at
least 26 weeks. The poor stabilization of HA by dextran
might be due to phase separation (during freezing) and/or the
bulkiness of dextran (steric hindrance), preventing efficient
vitrification and interaction (e.g. hydrogen bonding) with the
protein (58,89,112). This is in contrast to the small disac-
charide trehalose. The less efficient stabilization of HA at
elevated temperatures by the oligosaccharide inulin com-
pared to trehalose might be due to a lower extent and
intimacy of interaction (e.g. hydrogen bond formation) (89).
In the same study it was also found that HBS was
superior to PBS in preserving the in vitro immunological
properties of HA in the carbohydrate formulation upon
freeze-drying and storage. The antigen activity of the powders
decreased more readily when PBS was used instead of HBS.
Reasons for this could be an improper inclusion in the glassy
matrix due to the pH shift during freezing with PBS and the
capability of HBS to form an amorphous matrix (68) that acts
as a stabilizer during freeze-drying and storage.
Maa et al. evaluated the stability of trivalent influenza
subunit powder [containing A/Panama (H3N2), A/New Cale-
donia (H1N1) and B/Yamanashi strains] produced by spray-
freeze drying using highly concentrated feed solutions
(35.64 mg HA/ml and 35% w/v carbohydrate) (79). Vaccine
formulations of different compositions were evaluated for
stability:
& A: trehalose/mannitol/dextran 10 kD=3:3:4 (10% vaccine)
& B: trehalose/mannitol/arginine glutamate=4:2:4 (10% vaccine;
0.5% polysorbate80)
& C: trehalose/mannitol=7:3 (10% vaccine; 5% poloxamer 188)
During storage for 12 weeks at 40°C in sealed glass vials,
formulation A and B fully retained HA potency whereas Fig. 9. A pressure–temperature diagram for pure CO2.
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be due to decrease of the Tg by poloxamer. Although the HA
potency was unaffected, formulation B lost its uniform
particle properties (shape/flowability) during storage due to
crystallization of arginine glutamate. In an additional study
formulation A was found to be resistant to humidities of 10
and 40% relative humidity (RH) for 8 weeks at 40°C, but
gradually lost potency upon storage at 75% RH.
WIV vaccine powder stabilized with trehalose (trehalose/
virus, 500:1) as produced by Huang et al.s h o w e di m p r o v e d
stability compared to liquid WIV vaccine (85). While the liquid
formulation lost more than 50% of its haemagglutination
activity upon storage for 2 weeks at 4°C/25% RH and 25°C/
25% RH the powder formulation retained full haemagglutina-
tion activity up to 12 weeks. However, the powder formulation
showed an almost instant drop in stability upon storage at
40°C/75% RH. This was probably due to crystallization of
trehalose resulting from a decrease in Tg to below the storage
temperature by the high humidity resulting in an increase in
molecular mobility (62).
Inulin sugar glasses have been shown to preserve the
structural integrity and biological activity of influenza viro-
somes during storage (88). Virosomes (225–450 μg/ml)
lyophilized with inulin 1.8 kD (22.5–45 mg/ml) retained HA
potency upon storage for 12 weeks at 20°C. Upon storage at
42°C the inulin lyophilized virosomes gradually decreased in
HA potency, but to a lower extent than the virosomes
lyophilized without sugar. Moreover, virosome aggregation
upon storage and subsequent rehydration was visually
observed when virosomes were lyophilized without sugar,
but this did not occur when lyophilization was done in inulin.
The preservation of the vesicular structure in the presence of
sugars, in particular inulin is believed to be related to the fact
that the oligosaccharide interacts with membrane lipids and
as such may preserve the structural and functional features of
membrane vesicles during dehydration (64,113,114).
STABILIZATION OF DIFFERENT VACCINE
SUBTYPES
Although only limited research has been done on the
storage stability of different influenza vaccines, the extent of
stabilization seems to be related to the type of vaccine.
Especially the differences in complexity between WIV,
virosomes and split or subunit vaccines deserve attention.
The most successful stabilization studies have been per-
formed with subunit preparations, which are relatively stable
even at elevated temperatures. In contrast, WIV and viro-
somes incorporated in a glassy sugar matrix appeared to be
less stable at comparable conditions.
The main difference between subunit (and split) vaccine
compared to WIV and virosomes is the vesicular structure of
the latter consisting of lipids, which may explain the less
efficient stabilization of the WIV and virosomes. Lipids have
a melting point (Tm) above which they are in the liquid
crystalline phase; below this Tm they are in the gel phase. In
the hydrated state, for example the Tm for POPC (1-
Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) is about −1°C
and rises to about 70°C when it is dried without sugars (115).
This is due to increase in Van der Waal forces between lipids
upon removal of water molecules from the lipid headgroup
region. As a result the bilayer undergoes a phase transition
during rehydration, which may lead to disturbance of the vesicle
(Fig. 10). However, certain carbohydrates can prevent this
phase transition, according to the water replacement hypothesis
formulated by Crowe et al.( 66). Carbohydrates containing
many hydroxyl-groups can take over hydrogen bonding to a
certain extent, thereby forcing themselves in between the lipid
head groups. This results in more space between the lipid
molecules and reduction in Van der Waals forces, leading to
lower phase transition temperatures. For example, the Tm for
POPC in the dry state in the presence of trehalose is lowered to
−20°C (115). In addition carbohydrates that vitrify in between
the bilayers tend to keep the membrane in the phase it was at
t h em o m e n to fv i t r i f i c a t i o n( 116–118) and prevent aggregation/
fusion due to particle isolation (75).
Improved stability of vesicular lipid bilayer systems (like
liposomes,red bloodcells,or other mammaliancells)was found
when a stabilizer (like trehalose or inulin) was present at both
sides of the lipid bilayer (66,113–115,117,119). Lack of a
stabilizer in the vesicle interior can result in (partial) reorga-
nization of the lipids and subsequent phase transitions. In the
studies performed on stabilization of virosomes and WIV, the
inside of these vaccine particles lacked the presence of
carbohydrate, providing the opportunity of (partial) reorgani-
zation of the lipids and subsequent phase transitions. As a
result WIV and virosomes incorporated in sugar glasses might
have a reduced shelf-life compared to subunit and split
vaccines incorporated in sugar glass. Stabilization of lyophilized
virosomes may be improved by preparation of virosomes in the
presence of sugar (which results in sugar inside the virosome)
before formulation and lyophilization. Moreover, also stabili-
zation of WIV vaccines may be improved by loading WIV-
particles with sugar from an “extracellular” medium through a
combination of osmotic imbalance and phospholipid phase
transitions as has been shown to be successful for stabilization
of red blood cells (119). In addition, sugar uptake by WIV-
particles may be facilitated by increasing the membrane fluidity
with compounds such as benzyl alcohol or other weak
surfactants (119). In conclusion, stabilization of each type of
vaccine should be optimized individually.
Fig. 10. Water replacement hypothesis for lipid bilayers. The diagram
shows how trehalose is thought to stabilize dry lipid bilayers (adopted
from Crowe et al.( 66)).
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Determinants and Methods to Examine Vaccine
Stability/Integrity
The requirements for characterizing proteins/peptides
and vaccines are different. For the former, comprehensive
characterizations such as purity and degradation products are
required. For vaccines these are less stringent and normally
focuses on potency and immunigenicity. One of the methods
that often has been used to reveal integrity of the antigenic
structure of HA in vaccine formulations after the formulation
processes and/or storage is the single radial immunodiffusion
(SRID) assay. For several decades, this standardized method
has been used to determine the antigen content (HA potency)
of all human inactivated influenza vaccines, as recom-
mended by the European Pharmacopoeia and the WHO
(44,120). SRID is based on the diffusion of viral antigen in an
agarose gel containing specific antibodies to the antigen
measured.
However, for the determination of antigen integrity a
SRID assay may not be sufficient. The SRID assay is based
on the binding of antibodies to HA and does not address the
antigen’s stability. In case no structural alterations in HA are
detected by SRID this does not guarantee a complete absence
of conformational changes, since the method may not reveal
every structural change.
Although the value of treating vaccine formulations
using comparable standards as the pharmaceutical protein
products is not clear at this time, combining SRID analyses
with additional analytical techniques, like fluorescence spec-
troscopy, circular dichroism spectroscopy, surface plasmon
resonance transfer (SPR), asymmetric flow Field Flow
Fractionation (AFFF), reversed-phase high performance
liquid chromatography (RP-HPLC), electron microscopy
and the use of proteolytic assays may give more complete
information on the structural state of HA in the product.
However, even with the combination of all techniques it is
impossible to detect every possible structural change in large
and complex proteins like HA.
Vaccine Integrity vs. Immunogenicity
Until today only limited information is available on the
effects of structural changes of the vaccine compounds on the
final immune response in humans. The effects of low pH,
detergents or process stresses on the immunogenicity of the
vaccine may not be simply represented by changes in HA
potency determined in vitro. For this purpose well designed
studies using appropriate animal models or even human
volunteers should be conducted. In addition the critical
endpoints that are to be defined should be based on the
desired or expected type of immune response in relation to
the presentational form of HA, e.g. subunit, virosomal and
WIV. In a study of Babiuk et al. it was shown that changes in
the production process of influenza split vaccine can have
remarkable effects on the immunogenicity of the vaccine
(121), while no changes in HA potency may be revealed by
SRID. Due to a new viral splitting procedure the amount of
un-split virions and aggregates, in the split vaccine were
increased. This led to a change in the immune response to a
greater Th2 cytokine pattern with potential implications for
vaccine safety and efficacy. This shows that solely determin-
ing the HA content will not suffice as determinant for the
immunogenicity of the vaccine.
In addition, criteria should be formulated to address the
relevant physical and functional properties for each vaccine
type. For example WIV and virosomal vaccines may have
immunological advantages over subunit vaccine related to
their particulate form and/or ability to deliver material to the
cytoplasm of APCs. Therefore, appropriate criteria should be
formulated for these functional characteristics like fusion
activity. Strikingly, there is no criterion for vesicular size
mentioned in the European Pharmacopoeia for WIV vac-
cines, while on the other hand the size of virosomes should be
between 100 and 500 nm (120).
APPLICATION OF DRY INFLUENZA VACCINE
FORMULATIONS
Dried influenza vaccines, having an improved stability,
can be used for reconstitution and subsequent for con-
ventional parenteral administration. However, having the
vaccine in the dry state offers the opportunity to deliver the
vaccine via non-parenteral dosage forms. In the past decades
researchers have used dry influenza vaccine formulations for
the development of epidermal, oral, nasal or pulmonary
vaccines (Table II). However, the development of dry-state
influenza vaccine forms is still in a very early stage and for a
launch of an approved product, data on pre-clinical and
human clinical studies are needed besides data on (long-term)
stability.
The delivery methods using dry influenza vaccine
formulations that are tested in phase I clinical trials are
epidermal powder delivery and oral delivery (80,84,122,123).
During epidermal powder delivery, vaccine powder particles
with a high particle density and a particle size of 20–70 μm
are accelerated to a high speed with a powder jet injector
(PowderJect, PowderJect Pharmaceuticals) such that the
particles penetrate the stratum corneum and land in the
epidermis. Powders for epidermal immunization have been
made by both desiccation/grinding/sieving and spray-freeze
drying (78,79,82,83). Important factors for the design of
these powders were a high particle density and a particle size
of 20–70 μm for effective penetration to the epidermis (124).
In pre-clinical studies it was shown that immunization of
mice with influenza vaccine powder using the powder jet
injector results in antibody responses and protective immu-
nity against homologous and heterologous influenza viruses
(78,82,125,126). In the phase I clinical trial it was found that
epidermal powder immunization of human with influenza
vaccine powder using a PowderJect ND5.2 is safe and
induces humoral immune responses (126). In this trial it
was also found that compared to the conventional i.m.
vaccination seroconversion and geometric mean titers were
equivalent or higher after epidermal immunization with
influenza vaccine powder. Although this study showed
promising results additional studies with higher numbers of
subjects are needed to prove the safety and efficacy of
epidermal powder immunization.
Oral immunization of humans with influenza vaccine
powder has been studied in the 1980s. In clinical studies by
1269 Development of Stable Influenza Vaccine Powder FormulationsLazzell et al.( 80), Bergmann et al.( 123)a n dl a t e rb y
Moldoveanu et al.( 84) it was shown that ingestion of
inactivated influenza virus vaccine powders in enteric-coated
capsules stimulates local synthesis of secretory IgA (sIgA)
antibody in human nasal secretions. However, no systemic
immune responses were elicited from ingestion of the
vaccines, responses that are needed to fulfill regulatory
criteria for vaccine immunogenicity (127).
Nasal delivery of liquid LAIV vaccine is the only non-
parenteral immunization method that is commercialized so
far. Nasal delivery of influenza vaccine powders is attractive
since devices have been developed for intranasal delivery
(128), and intranasally delivery of droplets larger than 50 μm
is highly reproducible (129,130). One pre-clinical study on
nasal delivery of vaccine powders has been reported (85). In
the study of Huang et al. it was shown that nasal delivered
whole inactivated influenza vaccine powder co-formulated
with a mucoadhesive compound elicited significant serum
antibody and nasal IgA responses in rats. Clinical studies
should be performed to show the efficacy of this vaccine
powder in human.
Pulmonary delivery has been described as a promising
strategy for vaccination (128,131,132) and has recently been
evaluated in pre-clinical studies. In a study by Smith et al.i t
was shown that pulmonary delivery of a spray-dried lipid
formulation containing split influenza vaccine in rats resulted
in substantial systemic immune responses, but no mucosal
IgA in the respiratory tract (9). Also a SFD vaccine powder
has been evaluated for pulmonary vaccination. In the pre-
clinical study, pulmonary vaccination of mice with vaccine
powder resulted in the induction of mucosal, systemic
humoral and cell-mediated immune responses, which were
even higher than after i.m. immunization of mice with
conventional liquid vaccine (77). These pre-clinical studies
demonstrate the promising potential of dry powder inhalation
for influenza vaccination. However, until today the safety and
efficacy of influenza vaccination using appropriate dry
powder inhalers (DPI’s) is not proven in clinical trials.
CONCLUSIONS
From the investigations performed so far, it can be
concluded, that incorporation of influenza vaccines in amor-
phous glassy carbohydrate matrices has the potential to solve
the problems associated with the cold-chain requirement of
liquid vaccines. However, many aspects of the stabilization of
influenza vaccines, in particular the comparison between the
different drying methods for the production of stabilized
influenza vaccines, have to be further investigated. It is clear
that not all drying methods are suitable. In addition, each
vaccine type may possess its own intrinsic sensitivity to different
process stresses and have its own limitations, e.g., due to their
particulate nature, virosomes and WIV appear to possess a
highersensitivitytoshearstressesduringatomizationappliedby
spray (freeze) drying than subunit and split vaccines. As a result
the incorporation of a vaccine compound in carbohydrate
glasses should be optimized by both formulation and drying
process considerations. Moreover, not only vaccine-type-
dependent formulation and process design, but also the
analytical challenges as well as methods to establish the critical
parameters for vaccine stability, have to be addressed to
g u a r a n t e eas t a b l ea n de f f e c t i v es o l i di n f l u e n z av a c c i n e .S i n c e
the development of dry-state influenza vaccine is still in a very
earlystage,additional dataonlong-termstabilityofdryinfluenza
vaccine formulations and pre- and clinical studies are needed
before an approved product can be launched on the market.
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